Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • mavacamten

    - PMLiVE

    Amgen reports positive results from landmark cardiovascular study

    The study found significant reductions of major cardiovascular events in high-risk adults following treatment

    - PMLiVE

    Eli Lilly’s Mounjaro shown to provide cardiovascular protection in type 2 diabetes patients

    Approximately 38.4 million people in the US are affected by diabetes

    - PMLiVE

    Novartis and ProFound enter cardiovascular disease collaboration worth $750m per target

    The companies will aim to discover and develop new therapeutics for the group of disorders

    - PMLiVE

    Eli Lilly to expand cardiovascular disease pipeline with $1.3bn Verve acquisition

    The deal will give Lilly access to Verve’s pipeline of gene editing medicines for atherosclerotic CVD

    - PMLiVE

    NewAmsterdam’s CETP inhibitor obicetrapib shows promise in Alzheimer’s sub-study

    The trial was primarily designed to assess the LDL-C lowering efficacy of the candidate

    - PMLiVE

    Novo Nordisk’s GLP-1 drug Wegovy shows early protection against heart disease

    Heart and circulatory diseases are responsible for more than 170,000 deaths in the UK every year

    - PMLiVE

    Merck gains rights to Hengrui’s heart disease candidate in deal worth almost $2bn

    Cardiovascular diseases result in an estimated 17.9 million global deaths each year

    - PMLiVE

    AstraZeneca gains rights to CSPC’s lipid-lowering therapy in deal worth over $1.9bn

    Dyslipidaemia is estimated to result in 2.6 million global deaths every year

    - PMLiVE

    Novartis announces positive late-stage results for Leqvio monotherapy in atherosclerotic CVD

    Cardiovascular disease, including heart disease and stroke, is the leading cause of death globally

    - PMLiVE

    J&J to expand cardiovascular capabilities with V-Wave acquisition worth up to $1.7bn

    The company’s medtech division will gain access to a cardiovascular implant device for heart failure

    - PMLiVE

    Johnson & Johnson to expand cardiovascular capabilities with $13.1bn Shockwave acquisition

    Cardiovascular disease results in an estimated 17.9 million global deaths every year

    - PMLiVE

    Study reveals early menopause and higher CVD risk could be linked to cognitive decline

    Approximately 733,040 people in Canada are estimated to be living with dementia

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links